NVO

37.8202.70%
MH

Martin Holst Lange

EVP of R&D, Chief Scientific Officer and Member of the Management Board

Dr. Martin Holst Lange is Director of Pharmacosmos A/S. He has been Executive Vice President at Novo Nordisk A/S since March 2021 and served as its Executive Vice President of Development since 2023 until August 2025 and serves as its Chief Scientific officer from August 7, 2025 and serves as its Executive Vice President of R&D since August 2025 and serves as its Member of the Management Board since 2021.and served as its Head of Development until 2023. He joined Novo Nordisk in 2002, as first operationally and subsequently medically responsible for several projects within Global Development. From 2006 to 2008 he worked in Novo Nordisk Inc., USA, in the Medical Department as senior medical Director. In 2008, he moved back to Denmark and became Vice President, Medical & Science liraglutide, transferring in 2010 to insulin degludec in a similar position. From 2013 to 2017, he served as corporate project Vice President for Insulin & Diabetes Outcomes and subsequently Insulin & Devices. In January 2018, he was appointed Senior Vice President for Global Development. From 1997 to 2002, he did clinical work as well as clinical research of which the latter, several years at the Department of Endocrinology, National University Hospital, Denmark. Dr. Lange has served on the Board of Directors of Beta Bionics Inc., USA. He holds PhD in Endocrinology, University of Copenhagen, Denmark in 2004. He holds Doctor of Medicine (MD), University of Copenhagen, Denmark in 1997.

公司职务